PeptiDream announces strategic partnership and license option agreement with Amolyt Pharma

▴ PeptiDream announces strategic partnership and license option agreement with Amolyt Pharma
This collaboration will help both companies to work together to test and further optimize PeptiDream’s Growth Hormone Receptor Antagonist“GHRA” peptide candidates

PeptiDream Inc., a public Kanagawa-based biopharmaceutical company announced that it has entered into a strategic partnership and license option agreement with Lyon, FRANCE-based Amolyt Pharma, whereby both companies will work together to test and further optimize PeptiDream’s Growth Hormone Receptor Antagonist“GHRA” peptide candidates, with the goal of selecting a clinical candidate for development in acromegaly, a rare endocrine disorder with serious medical complications, to which Amolyt has an option to license the candidates for future clinical development.

Under the terms of the agreement, PeptiDream will be eligible for certain payments associated with the licensing, development, and commercial success of any GHRA product(s), as well as be eligible for certain royalties on future net sales.

“We are pleased to partner with PeptiDream, a leading Japanese biopharmaceutical company with an impressive technology platform for the design of new therapeutic peptides, and whose strategic partners include world class pharmaceutical companies. The potential expansion of our pipeline into acromegaly, where significant unmet needs persist, represents a perfect strategic fit for Amolyt. Given our extensive experience in developing therapeutic peptides to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases, including our lead clinical candidate, AZP-3601, for hypoparathyroidism, we believe we have the expertise to successfully bring a promising therapy to acromegaly patients in need,” said Thierry Abribat PhD, CEO of Amoylt Pharma.

“We believe Amolyt Pharma is the ideal partner to lead the development of our GHRA peptide candidates and potentially bring an improved treatment paradigm to patients suffering from acromegaly. We are impressed by their therapeutic peptide development capabilities and we are confident in entrusting them with advancing this potentially important asset. We look forward to a mutually beneficial partnership.” said Patrick C. Reid PhD, President & CEO of PeptiDream.

Tags : #PeptiDreamInc #LatestNewsonPeptiDreamInc9thDec #LatestPharmaNews9thDec #LatestPharmaCollaboration9thDec #AmolytPharma #LatestNewsonAmolytPharma9thDec

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Surviving Against the Odds: Steven Spinale's Journey After an Ingrown Hair Turns DeadlyMarch 29, 2024
10 reasons why media research and Planning are essential in Healthcare marketingMarch 29, 2024
The Surprising Link Between Sleep and Age Perception: What You Need to KnowMarch 29, 2024
The Dark Side of Beauty: Kidney Damage from Hair Straightening TreatmentsMarch 29, 2024
The Dark Side of Beauty: Kidney Damage from Hair Straightening TreatmentsMarch 29, 2024
Avance Clinical at World Vaccine Congress to Share Latest Vaccine Clinical Trial News Including an HIV-1 StudyMarch 29, 2024
Sexual wellness superstore, Love Depot launches digital campaign to deliver every desireMarch 28, 2024
Recharge Your Life: Simple Ways to Boost Your Physical and Mental EnergyMarch 28, 2024
The Neurological Toll of Common Household Chemicals: Insights from Recent ResearchMarch 28, 2024
The Aging Puzzle: Decoding the Mechanisms of AgingMarch 28, 2024
The Double-Edged Sword of Kala-azar Treatment: Shedding Light on Eye ComplicationsMarch 28, 2024
FTCCI Launches Industry-Academia Connect to improve the employability of Engineering Graduates and address the growing demand for Talent in Emerging TechMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
2nd Edition of IIFL JITO Ahimsa Run for peace & for non-violence to be held on 31st MarchMarch 27, 2024
Brij Hotels Announced 4 Million in Series A Funding March 27, 2024
Combatting Childhood Sedentariness: The Key to Preventing Premature Vascular DamageMarch 27, 2024
Crucial Findings: Unlocking Paths to Combat Ebola's DevastationMarch 27, 2024
Guarding Against Disease: The Crucial Role of Oral Hygiene in Preventive HealthcareMarch 27, 2024
Sanofi & Cipla announce exclusive distribution partnership to expand reach of CNS portfolio in IndiaMarch 26, 2024